Sun Pharma To Present Long-Term Follow-up Data On UNLOXCYT

Sun Pharmaceutical said it will share updated investigator-reviewed results from the locally advanced cutaneous squamous cell carcinoma expansion cohort of the CK-301-101 trial for UNLOXCYT at the ASCO 2026 Annual Meeting. The announcement is a routine clinical-trial update with no efficacy or safety data disclosed in the excerpt. Limited immediate market impact is likely absent further results.

Analysis

Sun Pharmaceutical said it will share updated investigator-reviewed results from the locally advanced cutaneous squamous cell carcinoma expansion cohort of the CK-301-101 trial for UNLOXCYT at the ASCO 2026 Annual Meeting. The announcement is a routine clinical-trial update with no efficacy or safety data disclosed in the excerpt. Limited immediate market impact is likely absent further results.